Abstract
We compared the effectiveness of albuterol with isoproterenol as a bronchodilator for use in pulmonary function testing. A total of 180 patients presenting for routine pulmonary function testing were randomly assigned to receive 5 mg of either albuterol or isoproterenol by compressed air nebulizer. Forced expiratory maneuvers were performed before, 5 min after, and 10 min after bronchodilator administration. The average increase in FEV1 and FVC did not differ between drugs. Also, the fraction of patients achieving a clinically significant bronchodilator response did not differ between drugs. Importantly, there was no significant difference between average 5 and 10 min postbronchodilator values for FEV1 or FVC for either bronchodilator, suggesting that a peak response was reached by 5 min. These results show no advantage of isoproterenol over albuterol in terms of potency or speed of action. Given the well-known cardiovascular side effects of isoproterenol, albuterol is the preferable agent for use in pulmonary function testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
